重组抗小鼠CTLA-4单抗(9D9)流式 | Syd Labs PA007501.h1Fs
Syd Labs重组抗小鼠CTLA-4单克隆抗体(克隆号9D9) ，人IgG1 Fc Silent Kappa(货号：PA007501.h1Fs)是用哺乳动物细胞生产的重组抗体，可用于流式细胞术和免疫组织化学-冷冻等研究，纯度>95%。其不变区为人Human IgG1 Kappa (hIgG1或h1)，可与重组人IgG1同型对照抗体配套使用。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。
产品参数
| 货号 | PA007501.h1Fs |
|---|---|
| 产品名称 | 重组抗小鼠CTLA-4单抗(9D9)流式 | Syd Labs PA007501.h1Fs |
| 英文名 | Recombinant Anti-mouse CTLA-4 Monoclonal Antibody (Clone: 9D9), Human IgG1 Fc Silent Kappa |
| 供货商名称 | Syd Labs, Inc. |
| 品牌名 | Syd Labs |
| 别称 | 细胞毒性 T 淋巴细胞相关抗原 4、细胞毒性 T 淋巴细胞抗原 4、CD152、CTLA4 |
| 概述 | Syd Labs提供重组人IgG1同型对照抗体。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。 |
| 克隆号 | 9D9 |
| 同种型 | 人 IgG1 kappa |
| 特异性 | 该重组 9D9 抗体与小鼠 CTLA-4 蛋白特异性结合 |
| 免疫源 | 重组抗小鼠CTLA-4单克隆抗体 (克隆：9D9)在哺乳动物细胞中产生 |
| 抗体形式 | 0.2微米过滤溶液，pH 7.4，含0.09%叠氮化钠 |
| 偶联 | 非偶联 |
| 纯度 | >95%（在还原条件下通过SDS-PAGE测定） |
| 运输 | 重组抗小鼠CTLA-4单克隆抗体(克隆号9D9) ，人IgG1 Fc Silent Kappa用冰袋运输。收到后，请立即将其存放在下面建议的温度下。 |
| 稳定性与存储 | 使用手动除霜冰箱并避免重复冻融循环。 自收到之日起 12个月，保存在2 至 8°C。 请勿冻结。 |
| 注意事项 | PA007501.h1Fs Syd Labs提供重组人IgG1同型对照抗体。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。 |
| 产品咨询 | Syd Labs在国内只通过代理商销售其产品，不做直销。终端用户咨询价格请联系Syd Labs中国代理商。 关于Syd Labs产品如果有任何技术或其它问题，欢迎随时联系Syd Labs国内市场推广合作伙伴：武汉多找找科技有限公司，企业微信：duozhaozhao2024 联系电话：18162581039（龙经理） |
| 应用详情 | 流式细胞术（FC）和免疫组织化学-冷冻（IHC-F）。 |
文献
重组抗小鼠CTLA-4单克隆抗体(克隆号9D9) ，人IgG1 Fc Silent Kappa（Recombinant Anti-mouse CTLA-4 Monoclonal Antibody (Clone: 9D9), Human IgG1 Fc Silent Kappa，货号：PA007501.h1Fs Syd Labs）
9D9抗体可阻断小鼠细胞毒性T淋巴细胞抗原-4（CTLA-4）。阻断CTLA-4可解除抑制信号，从而避免其削弱T淋巴细胞的活性。
细胞毒性T淋巴细胞抗原-4（CTLA-4）是一种抑制性分子，它与具有刺激作用的CD28竞争结合抗原呈递细胞（APC）上的B7。CTLA-4和CD28均表达于T细胞表面。
抗小鼠CTLA-4单抗(9D9)流式部分参考文献:
1. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma
Simpson TR, et al. J Exp Med. 2013 Aug 26;210(9):1695-710. PMID: 23878181
“The study investigates the mechanism of anti-CTLA-4 therapy using the 9D9 monoclonal antibody in a B16 melanoma mouse model. Tumor-infiltrating lymphocytes were isolated from B16 tumors 7 days after the final dose of anti-CTLA-4 mAb and stained with fluorescently conjugated antibodies against CD4, CD25, CTLA-4 (clone 9D9), FoxP3, CD103, CD8, and CD45.1. Flow cytometry, performed on a modified FACSCanto II cytometer and analyzed with FlowJo software, showed that Tregs were gated as CD4+ FoxP3+ tumor-infiltrating lymphocytes, with the frequency of CTLA-4+ Tregs determined. Anti-CTLA-4 therapy significantly increased CD8+ T cell infiltration in tumors, highlighting the Fc-dependent depletion of regulatory T cells as a key factor in therapeutic efficacy.”
2. Anti-CTLA-4 therapy broadens the melanoma-reactive CD4+ T cell response
Quezada SA, et al. Oncoimmunology. 2014;3(5):e29032. PMID: 24828551
“This study explores the effects of anti-CTLA-4 therapy using the 9D9 monoclonal antibody on melanoma-reactive CD4+ T cells. Splenocytes were harvested and stained with fluorescently conjugated antibodies against CD4, CD8, CD25, CD44, CTLA-4 (clone 9D9), and PD-1 for flow cytometry analysis. Tetramer staining identified melanoma-specific CD4+ T cells, revealing a 3-fold increase in their frequency following anti-CTLA-4 treatment. Polyfunctional cytokine production was assessed via intracellular staining, demonstrating that anti-CTLA-4 therapy enhances the melanoma-reactive CD4+ T cell response.”
3. CTLA-4 expression on activated T cells by flow cytometry with clone 9D9
Egen JG, et al. Immunity. 2006 Jun;24(6):803-14. PMID: 16751384
“This study examines CTLA-4 expression on activated T cells using the 9D9 monoclonal antibody. Activated T cells were stained with PE-conjugated anti-mouse CTLA-4 (clone 9D9), revealing rapid upregulation of CTLA-4 within 24 hours of activation via flow cytometry. CD4+ T cells from OT-II mice were stimulated with OVA peptide, showing CTLA-4 internalization post-stimulation. Blockade with anti-CTLA-4 enhanced T cell expansion, demonstrating the role of CTLA-4 in regulating T cell responses in animal models.”